Biomed Res Int:肝细胞再生在预测乙肝相关急性-慢性肝衰竭方面的价值

2021-04-28 MedSci原创 MedSci原创

目前,尚未清楚肝细胞再生在预测乙肝相关急性-慢性肝衰竭(HBV-ACLF)预后方面的价值。近日,研究人员希望构建一个新的评分系统,通过应用肝脏再生和肝脏损伤的血清学指标来预测患者3个月内的预后,研究结

目前,尚未清楚肝细胞再生在预测乙肝相关急性-慢性肝衰竭(HBV-ACLF)预后方面的价值。近日,研究人员希望构建一个新的评分系统,通过应用肝脏再生和肝脏损伤的血清学指标来预测患者3个月内的预后,研究结果已发表于Biomed Res Int。

研究纳入了对病情迅速恶化的慢性乙型肝炎患者,对其进行了90天的观察,随访终点是死亡或肝移植。在诊断急性-慢性肝衰竭(ACLF)时估计血清参数。采用Cox比例危险回归来确定独立的预后因素,建立一个新的预后评分系统,采用受试者操作特征(ROC)曲线来分析该模型的性能。

 

结果,研究共纳入308名HBV-ACLF患者,随机分为训练组(n = 206)和测试组(n = 102)。分析结果显示,肌酸(Cre)、年龄、总胆红素(TBil)、甲胎蛋白(AFP)和国际正常化比率(INR)是HBV-ACLF的独立预后因素。根据Cox回归分析的结果,研究人员计算了一个新的预后模型(命名为TACIA评分)。新模型的ROC下面积(AUROC)在训练组和测试组中分别为0.861和0.763,TACIA评分较低(<4.34)的患者生存时间更长(P <0.001)。

综上所述,该研究为HBV-ACLF患者建立了一个相关的预后评分系统,可有效预测患者的短期生存。

 

原始出处:

 

Xiaoping Wang, et al., Value of Liver Regeneration in Predicting Short-Term Prognosis for Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. Biomed Res Int. 2020 Aug 6;2020:5062873. doi: 10.1155/2020/5062873.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745812, encodeId=f7dd1e45812b3, content=<a href='/topic/show?id=a38d813560b' target=_blank style='color:#2F92EE;'>#肝细胞再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81356, encryptionId=a38d813560b, topicName=肝细胞再生)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Jun 20 00:43:16 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863552, encodeId=1282186355246, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 18 06:43:16 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635836, encodeId=96331635836a5, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 31 22:43:16 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919251, encodeId=7b411919251ae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 13 00:43:16 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963373, encodeId=58c89633e333, content=参考学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oq6ictJzbYn74fomj0c5NlQ&s=100&t=1556073720, createdBy=fe4d5202808, createdName=liyonghong, createdTime=Fri May 07 12:50:27 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611021, encodeId=55ae1611021eb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 30 05:43:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961248, encodeId=0bb2961248fd, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fc15488338, createdName=ms2000000503002496, createdTime=Wed Apr 28 16:47:49 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745812, encodeId=f7dd1e45812b3, content=<a href='/topic/show?id=a38d813560b' target=_blank style='color:#2F92EE;'>#肝细胞再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81356, encryptionId=a38d813560b, topicName=肝细胞再生)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Jun 20 00:43:16 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863552, encodeId=1282186355246, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 18 06:43:16 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635836, encodeId=96331635836a5, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 31 22:43:16 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919251, encodeId=7b411919251ae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 13 00:43:16 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963373, encodeId=58c89633e333, content=参考学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oq6ictJzbYn74fomj0c5NlQ&s=100&t=1556073720, createdBy=fe4d5202808, createdName=liyonghong, createdTime=Fri May 07 12:50:27 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611021, encodeId=55ae1611021eb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 30 05:43:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961248, encodeId=0bb2961248fd, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fc15488338, createdName=ms2000000503002496, createdTime=Wed Apr 28 16:47:49 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-05-18 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745812, encodeId=f7dd1e45812b3, content=<a href='/topic/show?id=a38d813560b' target=_blank style='color:#2F92EE;'>#肝细胞再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81356, encryptionId=a38d813560b, topicName=肝细胞再生)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Jun 20 00:43:16 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863552, encodeId=1282186355246, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 18 06:43:16 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635836, encodeId=96331635836a5, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 31 22:43:16 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919251, encodeId=7b411919251ae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 13 00:43:16 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963373, encodeId=58c89633e333, content=参考学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oq6ictJzbYn74fomj0c5NlQ&s=100&t=1556073720, createdBy=fe4d5202808, createdName=liyonghong, createdTime=Fri May 07 12:50:27 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611021, encodeId=55ae1611021eb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 30 05:43:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961248, encodeId=0bb2961248fd, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fc15488338, createdName=ms2000000503002496, createdTime=Wed Apr 28 16:47:49 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1745812, encodeId=f7dd1e45812b3, content=<a href='/topic/show?id=a38d813560b' target=_blank style='color:#2F92EE;'>#肝细胞再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81356, encryptionId=a38d813560b, topicName=肝细胞再生)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Jun 20 00:43:16 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863552, encodeId=1282186355246, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 18 06:43:16 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635836, encodeId=96331635836a5, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 31 22:43:16 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919251, encodeId=7b411919251ae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 13 00:43:16 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963373, encodeId=58c89633e333, content=参考学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oq6ictJzbYn74fomj0c5NlQ&s=100&t=1556073720, createdBy=fe4d5202808, createdName=liyonghong, createdTime=Fri May 07 12:50:27 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611021, encodeId=55ae1611021eb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 30 05:43:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961248, encodeId=0bb2961248fd, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fc15488338, createdName=ms2000000503002496, createdTime=Wed Apr 28 16:47:49 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2022-03-13 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1745812, encodeId=f7dd1e45812b3, content=<a href='/topic/show?id=a38d813560b' target=_blank style='color:#2F92EE;'>#肝细胞再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81356, encryptionId=a38d813560b, topicName=肝细胞再生)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Jun 20 00:43:16 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863552, encodeId=1282186355246, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 18 06:43:16 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635836, encodeId=96331635836a5, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 31 22:43:16 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919251, encodeId=7b411919251ae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 13 00:43:16 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963373, encodeId=58c89633e333, content=参考学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oq6ictJzbYn74fomj0c5NlQ&s=100&t=1556073720, createdBy=fe4d5202808, createdName=liyonghong, createdTime=Fri May 07 12:50:27 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611021, encodeId=55ae1611021eb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 30 05:43:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961248, encodeId=0bb2961248fd, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fc15488338, createdName=ms2000000503002496, createdTime=Wed Apr 28 16:47:49 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-05-07 liyonghong

    参考学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1745812, encodeId=f7dd1e45812b3, content=<a href='/topic/show?id=a38d813560b' target=_blank style='color:#2F92EE;'>#肝细胞再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81356, encryptionId=a38d813560b, topicName=肝细胞再生)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Jun 20 00:43:16 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863552, encodeId=1282186355246, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 18 06:43:16 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635836, encodeId=96331635836a5, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 31 22:43:16 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919251, encodeId=7b411919251ae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 13 00:43:16 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963373, encodeId=58c89633e333, content=参考学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oq6ictJzbYn74fomj0c5NlQ&s=100&t=1556073720, createdBy=fe4d5202808, createdName=liyonghong, createdTime=Fri May 07 12:50:27 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611021, encodeId=55ae1611021eb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 30 05:43:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961248, encodeId=0bb2961248fd, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fc15488338, createdName=ms2000000503002496, createdTime=Wed Apr 28 16:47:49 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1745812, encodeId=f7dd1e45812b3, content=<a href='/topic/show?id=a38d813560b' target=_blank style='color:#2F92EE;'>#肝细胞再生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81356, encryptionId=a38d813560b, topicName=肝细胞再生)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Jun 20 00:43:16 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863552, encodeId=1282186355246, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 18 06:43:16 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635836, encodeId=96331635836a5, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Tue Aug 31 22:43:16 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919251, encodeId=7b411919251ae, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 13 00:43:16 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963373, encodeId=58c89633e333, content=参考学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=oq6ictJzbYn74fomj0c5NlQ&s=100&t=1556073720, createdBy=fe4d5202808, createdName=liyonghong, createdTime=Fri May 07 12:50:27 CST 2021, time=2021-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611021, encodeId=55ae1611021eb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Apr 30 05:43:16 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961248, encodeId=0bb2961248fd, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fc15488338, createdName=ms2000000503002496, createdTime=Wed Apr 28 16:47:49 CST 2021, time=2021-04-28, status=1, ipAttribution=)]
    2021-04-28 ms2000000503002496

    好文

    0

相关资讯

拨丝抽茧-如何看待HBeAg与HBeAb“共生”

乙肝两对半检测是临床上判读乙肝病毒感染的最简单有效的方式,乙肝两对半一共有乙肝表面抗原(HBsAg)、乙肝表面抗体(抗-HBs)、乙肝e抗原(HBeAg)、乙肝e抗体(抗-HBe)及乙肝核心抗体(抗-

Eur Radiol:脾脏体积的测量是否可评价乙型病毒性肝硬化代偿的高危静脉曲张的高危性?

超过一半的肝硬化患者没有胃食管静脉曲张的发生,使得内窥镜检查的阳性率较低。因此,建立一种检测肝硬化患者的高风险静脉曲张存在的非侵入性检查方式十分重要。

J Hepatology: HBsAg的不同成分可预测HBeAg阳性慢性乙型肝炎患者治疗期间HBsAg的流失情况

慢性乙型肝炎(CHB)病毒感染是全球性的公共卫生问题,全球估计有2.5亿慢性感染者。

J Hepatology:中科院胡荣贵团队揭示为什么大多数人感染乙肝病毒后会自行痊愈

乙型肝炎病毒感染是一个重要的全球性健康问题,是导致肝炎的主要原因之一。目前世界上乙型肝炎病毒的慢性感染病例数为3.5到4亿,75%的被感染者是亚洲人。中国HBV感染相关的肝病和肝癌极为常见,每年造成4

RNAi药物治疗乙肝的新药RG6346,疗效强且持久超过1年

Dicerna Pharmaceuticals与罗氏(Roche)合作开发,治疗慢性乙肝病毒(HBV)感染的RNAi疗法RG6346,在1期临床试验中的最新结果进行公布。试验结果显示,每月一次,总计4

Dig Dis Sci:慢性乙型肝炎患者晚期肝纤维化与坏死性炎症相关与肝脂肪变性无关

慢性乙型肝炎(CHB)是一个全球性的健康问题,全球约有2.5亿人受到影响,患有CHB的人会发生各种不良后果,例如肝失代偿,肝硬化和肝细胞癌(HCC)。